antibiotics is one of 259 small molecule programs targeting Premature rupture of membranes. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
199 competitors in Lung Cancer
Keytruda
Imfinzi
Yervoy
Abraxane
Alecensa
Zepzelca
DATROWAY
Lynparza
Tarlatamab-Dznl
Ilaris
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details